VanEck Pharmaceutical ETF PPH
121.56 USD +2.96 (+2.50%)
Nov 4, 2026, 2:58 PM EST
119.63 Day range 121.83
92.60 52-week range 121.83
- YTD
- +17.82%
- 1 year
- +31.06%
- Market cap
- 1.13B
- EPS (ttm)
- 4.37
- P/E ratio
- 27.78
- YTD return
- +17.82%
- 1-year return
- +31.06%
- Volume
- 390.69K
- Avg volume
- 313.65K
- Open
- 121.50
- Previous close
- 118.60
- Day's range
- 119.63 – 121.83
- 52-week range
- 92.60 – 121.83
1D 0.00 (0.00%)
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 112.64
- 200-day average
- 107.98
About VanEck Pharmaceutical ETF
The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The index includes common stocks and depositary receipts of U.S. exchange-listed companies in the pharmaceutical industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.
News
Can GLP-1s Fatten Your Portfolio? We Examine the VanEck Pharmaceutical ETF vs State Street SPDR Pharmaceuticals ETF 
PPH: Key Pharmaceutical Innovations Support Bullish Outlook (Upgrade) 
Which Pharmaceutical ETF Is the Better Buy: iShares’ Domestic IHE or VanEck’s Global PPH? 
Which Healthcare ETF Is the Better Buy: Simplify's Active PINK or VanEck's Pharma-Focused PPH? 
Execution of Pharma Tariffs Brings These ETFs Into Focus 
Should You Invest in the VanEck Pharmaceutical ETF (PPH)? 
Better Pharmaceuticals ETF: VanEck's PPH vs. Invesco PJP 
VanEck Pharmaceutical ETF vs VanEck Biotech ETF: Which Fund Is Better for Drug Innovation Profits? 
Should You Bet Big on Drugmakers? VanEck Pharmaceutical ETF vs. 
Healthcare ETFs to Watch Post Merck-Moderna Cancer Vaccine Breakthrough
Your note
Sign in to keep a note on PPH — it syncs with the Stock Master app.